Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm, Residual 1Multiple Myeloma 1Giant Cell Tumor of Bone 1Disease Progression 1Colorectal Neoplasms 1

Interventions

blinatumomab 5midostaurin 2Azacitidine 2venetoclax 1tisagenlecleucel 1siremadlin 1sabatolimab 1pulrodemstat besilate 1posaconazole 1fludarabine phosphate 1fludarabine 1Zoledronic Acid 1Vitamin D 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Midazolam 1Idarubicin 1Drug Therapy 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Calcium 1CD3 Complex 1Anthracyclines 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm, Residual × Calcium × Clear all
NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated
96 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡